DK1056452T3 - Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter - Google Patents

Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter

Info

Publication number: DK1056452T3
Authority: DK; Denmark
Prior art keywords: indole; propionic acid; ester; salt; effective amount
Prior art date: 1998-02-23

Application number

DK99908381T

Other languages

English (en)

Inventor

Jorge Ghiso

Burkhard Poeggeler

Miguel A Pappolla

Blas Frangione

Original Assignee

Univ South Alabama

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-23

Filing date

1999-02-23

Publication date

2006-11-20

1999-02-23 Application filed by Univ South Alabama, Univ New York filed Critical Univ South Alabama

2006-11-20 Application granted granted Critical

2006-11-20 Publication of DK1056452T3 publication Critical patent/DK1056452T3/da

Links

GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 title abstract 10
150000002148 esters Chemical class 0.000 title abstract 5
239000003290 indole 3-propionic acid Substances 0.000 title abstract 5
150000003839 salts Chemical class 0.000 title abstract 5
239000003814 drug Substances 0.000 title 1
239000012472 biological sample Substances 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
230000035557 fibrillogenesis Effects 0.000 abstract 1
230000002600 fibrillogenic effect Effects 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
230000036542 oxidative stress Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)

DK99908381T 1998-02-23 1999-02-23 Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter DK1056452T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7555598P	1998-02-23	1998-02-23
US11256598P	1998-12-16	1998-12-16

Publications (1)

Publication Number	Publication Date
DK1056452T3 true DK1056452T3 (da)	2006-11-20

Family

ID=26757006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK99908381T DK1056452T3 (da)	1998-02-23	1999-02-23	Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter

Country Status (17)

Country	Link
US (1)	US6395768B1 (da)
EP (1)	EP1056452B1 (da)
JP (2)	JP5627160B2 (da)
CN (1)	CN1147299C (da)
AT (1)	ATE333275T1 (da)
AU (1)	AU757925B2 (da)
BR (1)	BR9908165A (da)
CA (1)	CA2321455C (da)
DE (1)	DE69932414T2 (da)
DK (1)	DK1056452T3 (da)
EA (1)	EA005244B1 (da)
ES (1)	ES2270585T3 (da)
IL (2)	IL137848A0 (da)
MX (1)	MXPA00008216A (da)
NZ (1)	NZ506260A (da)
PT (1)	PT1056452E (da)
WO (1)	WO1999042102A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720355B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Sodium dodecyl sulfate compositions for inactivating prions
US6419916B1 (en)	1999-06-01	2002-07-16	The Regents Of The University Of California	Assay for compounds which affect conformationally altered proteins
US6719988B2 (en)	1997-02-21	2004-04-13	The Regents Of The University Of California	Antiseptic compositions for inactivating prions
US6322802B1 (en)	1999-06-01	2001-11-27	The Regents Of The University Of California	Method of sterilizing
DE10006139A1 (de) *	2000-02-11	2001-08-16	Merck Patent Gmbh	Indol-3-yl-Derivate
US7491699B2 (en)	2002-12-09	2009-02-17	Ramot At Tel Aviv University Ltd.	Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de)	2003-01-07	2009-04-15	Univ Ramot	Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
EP1648867B1 (en) *	2003-07-17	2013-09-04	Plexxikon Inc.	Ppar active compounds
US7348338B2 (en) *	2003-07-17	2008-03-25	Plexxikon, Inc.	PPAR active compounds
US7125861B2 (en) *	2003-07-31	2006-10-24	Rolland F Hebert	Water-soluble chitosan-indole-3-propionic acid conjugates
JP4917889B2 (ja)	2003-09-25	2012-04-18	テルアヴィヴユニヴァーシティフューチャーテクノロジーディヴェロップメントエル．ピー．	アミロイド関連疾患を処置するための組成物及びその使用方法
WO2005031362A2 (en)	2003-10-02	2005-04-07	Ramot At Tel Aviv University Ltd.	Novel antibacterial agents and methods of identifying and utilizing same
US20070105937A1 (en) *	2003-12-22	2007-05-10	Miguel Pappolla	Indole-3-propionamide and derivatives thereof
WO2006013552A2 (en)	2004-08-02	2006-02-09	Ramot At Tel Aviv University Ltd.	Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de)	2004-08-19	2012-01-15	Univ Tel Aviv Future Tech Dev	Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
EP1819673A2 (en) *	2004-11-30	2007-08-22	Plexxikon, Inc.	Indole derivatives for use as ppar active compounds
WO2006060535A2 (en) *	2004-11-30	2006-06-08	Plexxikon, Inc.	Indole derivatives for use as ppar active compounds
EP1893576A4 (en) *	2005-05-27	2010-03-17	Univ Kingston	TREATMENT OF PROTEIN DISORDERING
AU2006287528A1 (en) *	2005-09-07	2007-03-15	Plexxikon, Inc.	1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds
KR20080042170A (ko) *	2005-09-07	2008-05-14	플렉시콘, 인코퍼레이티드	Ｐｐａｒ 활성 화합물
US10004828B2 (en)	2005-10-11	2018-06-26	Romat at Tel-Aviv University Ltd.	Self-assembled Fmoc-ff hydrogels
JP2010501591A (ja) *	2006-08-23	2010-01-21	インテレクト・ニューロサイエンシズ・インコーポレーテッド	３−（３−インドリル）プロピオン酸カルシウム塩およびそれから３−（３−インドリル）プロピオン酸の遊離酸を作る方法
PE20090159A1 (es) *	2007-03-08	2009-02-21	Plexxikon Inc	COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US9744155B2 (en)	2012-03-28	2017-08-29	Ixcela, Inc.	IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CN105934520A (zh) *	2014-01-31	2016-09-07	伊克斯塞拉有限公司	作为生物标志物的共价键代谢物
CN108125950B (zh) *	2017-12-28	2020-09-25	崔明	吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2020083827A (ja) *	2018-11-27	2020-06-04	国立研究開発法人農業・食品産業技術総合研究機構	ケミカルシャペロンまたは神経細胞死の抑制剤
US11041847B1 (en)	2019-01-25	2021-06-22	Ixcela, Inc.	Detection and modification of gut microbial population
CN109674787A (zh) *	2019-02-01	2019-04-26	百迈康生物医药科技(广州)有限公司	一种防治缺血性心脏病的药物及其应用
CN109730993A (zh) *	2019-02-28	2019-05-10	北京大学人民医院(北京大学第二临床医学院)	吲哚丙酸在制备防治类风湿关节炎药物中的应用
WO2020185913A1 (en) *	2019-03-12	2020-09-17	Intellect Neurosciences, Inc.	Indole-3-propionic acids and salts and esters thereof for treating skin disorders
WO2021123419A1 (en) *	2019-12-20	2021-06-24	Basf Se	Composition for the treatment of amyloid-beta associated diseases
CN118141804A (zh) *	2024-03-06	2024-06-07	浙江大学	吲哚-3-丙酸在制备用于增敏肿瘤免疫治疗的药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4536505A (en) *	1983-05-17	1985-08-20	Ciba-Geigy Corporation	Certain N-(pyridyl) indoles
JP2602735B2 (ja) *	1989-09-27	1997-04-23	株式会社大塚製薬工場	抗活性酸素剤
JPH0578247A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
JPH0578248A (ja) *	1991-03-04	1993-03-30	Mitsubishi Gas Chem Co Inc	活性酸素消去剤
WO1993010087A1 (en) *	1991-11-18	1993-05-27	G.D. Searle & Co.	Derivatives of cyclic phenolic thioethers as inhibitors or stimulators of superoxide generation
WO1994003427A1 (en) *	1992-08-06	1994-02-17	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IT1265101B1 (it) *	1993-07-23	1996-10-30	Erba Carlo Spa	Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
JPH0881442A (ja) *	1994-07-14	1996-03-26	Otsuka Pharmaceut Co Ltd	環状アミド誘導体
MX9700696A (es) *	1994-07-27	1997-04-30	Sankyo Co	Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
JPH08175993A (ja) *	1994-12-21	1996-07-09	Green Cross Corp:The	抗酸化剤
JPH09249567A (ja) *	1996-01-12	1997-09-22	Otsuka Pharmaceut Co Ltd	医薬組成物
TW430660B (en) *	1996-05-30	2001-04-21	Mochida Pharm Co Ltd	Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them

1999
- 1999-02-23 JP JP2000532118A patent/JP5627160B2/ja not_active Expired - Fee Related
- 1999-02-23 AT AT99908381T patent/ATE333275T1/de active
- 1999-02-23 MX MXPA00008216A patent/MXPA00008216A/es active IP Right Grant
- 1999-02-23 EA EA200000874A patent/EA005244B1/ru not_active IP Right Cessation
- 1999-02-23 PT PT99908381T patent/PT1056452E/pt unknown
- 1999-02-23 DE DE69932414T patent/DE69932414T2/de not_active Expired - Lifetime
- 1999-02-23 CN CNB998032441A patent/CN1147299C/zh not_active Expired - Fee Related
- 1999-02-23 EP EP99908381A patent/EP1056452B1/en not_active Expired - Lifetime
- 1999-02-23 AU AU27828/99A patent/AU757925B2/en not_active Ceased
- 1999-02-23 DK DK99908381T patent/DK1056452T3/da active
- 1999-02-23 BR BR9908165-2A patent/BR9908165A/pt not_active Application Discontinuation
- 1999-02-23 CA CA2321455A patent/CA2321455C/en not_active Expired - Lifetime
- 1999-02-23 WO PCT/US1999/003906 patent/WO1999042102A1/en not_active Ceased
- 1999-02-23 NZ NZ506260A patent/NZ506260A/en not_active IP Right Cessation
- 1999-02-23 ES ES99908381T patent/ES2270585T3/es not_active Expired - Lifetime
- 1999-02-23 IL IL13784899A patent/IL137848A0/xx unknown
2000
- 2000-05-30 US US09/580,437 patent/US6395768B1/en not_active Expired - Lifetime
- 2000-08-14 IL IL137848A patent/IL137848A/en not_active IP Right Cessation
2011
- 2011-10-20 JP JP2011230632A patent/JP2012017343A/ja active Pending

Also Published As

Publication number	Publication date
HK1036588A1 (en)	2002-01-11
EP1056452A1 (en)	2000-12-06
BR9908165A (pt)	2000-10-31
EP1056452B1 (en)	2006-07-19
DE69932414T2 (de)	2007-02-22
JP5627160B2 (ja)	2014-11-19
JP2012017343A (ja)	2012-01-26
ES2270585T3 (es)	2007-04-01
IL137848A (en)	2010-11-30
AU2782899A (en)	1999-09-06
WO1999042102A1 (en)	1999-08-26
EA200000874A1 (ru)	2001-02-26
AU757925B2 (en)	2003-03-13
CN1292693A (zh)	2001-04-25
CA2321455C (en)	2010-10-19
NZ506260A (en)	2003-05-30
CN1147299C (zh)	2004-04-28
CA2321455A1 (en)	1999-08-26
EA005244B1 (ru)	2004-12-30
IL137848A0 (en)	2001-10-31
MXPA00008216A (es)	2004-11-22
WO1999042102A8 (en)	2001-02-15
PT1056452E (pt)	2006-12-29
ATE333275T1 (de)	2006-08-15
JP2002503691A (ja)	2002-02-05
US6395768B1 (en)	2002-05-28
DE69932414D1 (de)	2006-08-31

Publication	Publication Date	Title
DK1056452T3 (da)	2006-11-20	Indol-3-propionsyre, salte og estere deraf anvendt som medikamenter
ES2056854T3 (es)	1994-10-16	Tiadiazinonas.
ATE262900T1 (de)	2004-04-15	Therapeutische und lebensmittel-zusammensetzungen,welche essentielle fettsäuren und bioaktive disulfide enthalten
NO904378D0 (no)	1990-10-10	Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
IT1176916B (it)	1987-08-18	Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
DE122005000001I2 (de)	2006-02-09	Zweiwertige Metallsalze von 2-N, N-di(carboxymethyl)-amino-3-cyano-4-carboxymethyl-5-carboxy-thiophens{ure, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE69004081D1 (de)	1993-11-25	Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
NO914217D0 (no)	1991-10-28	Sakkarinderivater nyttige som proteolytiske enzyminhibitorer og fremstilling derav
SE7902742L (sv)	1979-09-29	Disubstituerade 3-cefem-4-karboxylsyraderivat samt forfarande for framstellning derav
ATE84716T1 (de)	1993-02-15	4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelialgewebekrankheiten.
ATE311191T1 (de)	2005-12-15	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE126061T1 (de)	1995-08-15	Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
SE8801710D0 (sv)	1988-05-05	New ophtalmological composition of matter
TR200100897T2 (tr)	2001-10-22	Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
IT8721115A0 (it)	1987-06-30	Fitopreparato per la cura di affezioni cutanee.
GR3006674T3 (da)	1993-06-30
ATE5256T1 (de)	1983-11-15	Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
Kadam et al.	2019	Treatment of gingival recession defect using human umbilical cord mesenchymal stem cells cultured on PCL based bone regenerating scaffold: a randomized controlled clinical study
DE69807672D1 (de)	2002-10-10	Von milchsäure abgeleitete butyrat-prodrugs
NO890801D0 (no)	1989-02-24	Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.
ATE79265T1 (de)	1992-08-15	Mittel zur behandlung mykotischer, mikrobischer und anderer gewebsschaedigender und pathologischer manifestationen und gewebsdeformationen.
ATE2746T1 (de)	1983-03-15	Piperidinderivate von 4,5-dialkyl-3-hydroxypyrrol-2-carbons[ureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
ES2191825T3 (es)	2003-09-16	Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
DE69734349D1 (de)	2006-02-23	Behandlung von knochenleiden mit adrenomedullin